FITC CONJUGATED MONOCLONAL ANTIBODY TO HUMAN TCC (C9 NEOANTIGEN)

clone aE11

Catalog no HM2167F (lot number and expiry date are indicated on the label)

Description Monoclonal antibody aE11 reacts with a C9 neoantigen of the terminal complement complex (TCC). The three distinct activation pathways of complement converge with the formation of a C5 convertase. The cleavage of C5 by this convertase initiates the lytic or terminal pathway. In contrast to the activation pathways, which require enzymatic cleavage for activation, the terminal pathway relies on conformational changes induced by binding. Binding of C6 facilitates binding of C7 which alters the conformation of the complex. After binding of C8, a variable number of C9 molecules associate with the C5b678 complex, which is also termed the terminal complement complex (TCC). The formation of TCC causes lysis of cells or can trigger a variety of cellular metabolic pathways resulting in the synthesis and release of inflammatory mediators. The TCC contains neoantigens that are absent from the individual native components. C9 neoantigens are present both in the membrane-bound (MAC) and the fluid-phase (SC5b-9) complex. TCC is present in normal human plasma and increased in patients with complement activation.

Aliases MAC, membrane attack complex, sC5b-9 complex

Species Mouse IgG2a

Cross reactivity

<table>
<thead>
<tr>
<th>Cross reactant</th>
<th>Reactivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Horse</td>
<td>Yes</td>
</tr>
<tr>
<td>Swine</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Formulation 1 ml (100 µg/ml) 0.2 µm filtered FITC conjugated antibody solution in PBS, containing 0.1% bovine serum albumin and 0.02% sodium azide

Application

<table>
<thead>
<tr>
<th>F&lt;sup&gt;6&lt;/sup&gt;</th>
<th>FC&lt;sup&gt;5&lt;/sup&gt;</th>
<th>FS&lt;sup&gt;3,5&lt;/sup&gt;</th>
<th>IA&lt;sup&gt;1,2&lt;/sup&gt;</th>
<th>IF&lt;sup&gt;2,4&lt;/sup&gt;</th>
<th>IP</th>
<th>P&lt;sup&gt;4&lt;/sup&gt;</th>
<th>W&lt;sup&gt;2&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>●</td>
<td>N.D.</td>
</tr>
<tr>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

N.D. = Not Determined; F = Frozen sections; FC = Flow Cytometry; FS = Functional Studies; IA = Immuno Assays; IF = Immuno Fluorescence; IP = Immuno Precipitation; P = Paraffin sections; W = Western blot

Application notes FS: Antibody aE11 inhibits platelet activation by antiphospholipid antibody serum. (Ref.5).

References


Use For immunohistochemistry and flow cytometry dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

Positive control Mucosa from patients with H. Pylori.
**Storage and stability**

Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.

**Precautions**

For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.

**Also available**

- HM2167  Monoclonal antibody against TCC, clone aE11
- HM2061  Monoclonal antibody against MBL, clone MBL
- HM2073  Monoclonal antibody against C3/C3a, clone 474
- HM2077  Monoclonal antibody against C5/C5a, clone S57
- HM2094  Monoclonal antibody against C5aR, clone S5/1
- HP9036  Polyclonal antibody against CSL2